GSK to showcase latest research at the International RSV Symposium to advance RSV prevention in adults: London, UK Saturday, March 8, 2025, 14:00 Hrs [IST] GSK plc will share its ...

GSK has become the first pharma company to get regulatory approval for a vaccine against respiratory syncytial virus (RSV), setting up what looks set to be a highly lucrative – and likely ...

The FDA has approved Pfizer’s respiratory syncytial virus (RSV) vaccine for older adults, just a few weeks after a rival shot from GSK became the first to be cleared in the US. Pfizer’s ...

Life science companies developing bird flu vaccines are gaining attention as the avian influenza subtype H5N1 becomes an increasing concern. The United States is in the midst of an H5N1 bird flu ...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

GSK’s Arexvy, which became the first RSV vaccine approved in 2023 and protects older adults, reached about $734 million in sales in 2024, down 52% from the previous year, according to the ...

Britain's health regulator said on Friday it has approved Moderna's vaccine for respiratory syncytial virus in adults 60 ...

Under RFK Jr., HHS has canceled key vaccine meetings. Here's what that means for seasonal flu, bird flu, and childhood ...

Funding for this work has been provided by GSK. Editorial assistance was provided by ... Considerations for a Respiratory ...

Life science companies developing bird flu vaccines are gaining attention as the avian influenza subtype H5N1 becomes an ...

After predicting growth in vaccine sales in July of last year, poor performance from GSK’s Respiratory Syncytial Virus vaccine Arexvy led to an overall 4 percent drop in vaccine sales.